Why AKTS? Aktis Oncology, Inc. Analysis, Price & AI Insights | Whystock
AKTS
$19.42+0.67 (+3.57%)
Market ClosedLast close May 1
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.